PubMed Health⌕ Search

PubMed · 6395673

Nonhuman primate models for human disease.

Abstract

The value of nonhuman primates as models for a variety of human diseases is well documented. These species have been used extensively during the past 25 years or so as models for a variety of bacterial, viral, and parasitic diseases, either as naturally occurring or experimentally induced infections. They are often the only nonhuman species susceptible to experimental infection with agents of human disease. Spontaneous diseases of nonhuman primates are often comparable to human diseases, and with the continued long-term maintenance of nonhuman primates in the laboratory as well as in domestic breeding colonies, it is reasonable to assume that additional disease models will be discovered. Such models may include degenerative diseases, diseases and/or lesions associated with the aging process, and genetic diseases. In this article we have reviewed four spontaneous diseases and one induced disease that have essentially identical counterparts in humans. Three of these are bacterial diseases that currently cause severe and sometimes fatal infections in humans; one is a degenerative disease that is usually progressive and fatal in humans, and one is possibly a genetic disease for which there is currently no animal model. The clinical and pathologic similarities between these nonhuman primate diseases and their human counterpart make these nonhuman primate diseases potentially valuable models for further studies on the etiology, pathogenesis, and treatment of these serious and often fatal human diseases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H M McClure. 1984. Nonhuman primate models for human disease.. https://doi.org/10.1016/b978-0-12-039228-5.50014-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of multiple myeloma.

Autologous peripheral blood stem cell (PBSC)-supported high-dose melphalan is now considered standard therapy for myeloma, at least for younger patients. The markedly reduced toxicity of allotransplants using nonmyeloablative regimens (mini-allotransplantations) may hold promise for more widely exploiting the well-documented graft-versus-myeloma (GVM) effect. New active drugs include immunomodulatory agents, such as thalidomide and CC-5013 (Revimid; Celgene, Warren, NJ), and the proteasome inhibitor, PS 341 (Velcade; Millenium, Cambridge, MA), all of which not only target myeloma cells directly but also exert an indirect effect by suppressing growth and survival signals elaborated by the bone marrow microenvironment's interaction with myeloma cells. Among the prognostic factors evaluated, cytogenetic abnormalities (CAs), which are present in one third of patients with newly diagnosed disease, identify a particularly poor prognosis subgroup with a median survival not exceeding 2 to 3 years. By contrast, in the absence of CAs, 4-year survival rates of 80% to 90% can be obtained with tandem autotransplantations. Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup.

Amyloidosis↗

A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.

Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues, often with serious pathological consequences. Non-neuropathic systemic amyloidosis is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.

Amyloidosis↗